Your browser is no longer supported. Please, upgrade your browser.
AGTC Applied Genetic Technologies Corporation monthly Stock Chart
Applied Genetic Technologies Corporation
Index- P/E- EPS (ttm)-2.14 Insider Own0.30% Shs Outstand25.82M Perf Week7.16%
Market Cap111.32M Forward P/E- EPS next Y-2.09 Insider Trans0.00% Shs Float25.63M Perf Month-15.40%
Income-49.70M PEG- EPS next Q-0.59 Inst Own69.00% Short Float3.56% Perf Quarter-16.05%
Sales2.50M P/S44.53 EPS this Y2.30% Inst Trans-5.50% Short Ratio3.20 Perf Half Y-9.21%
Book/sh2.18 P/B1.99 EPS next Y1.40% ROA-53.30% Target Price- Perf Year55.00%
Cash/sh2.60 P/C1.67 EPS next 5Y- ROE-73.10% 52W Range2.29 - 10.42 Perf YTD-3.98%
Dividend- P/FCF- EPS past 5Y-7.80% ROI-58.30% 52W High-58.35% Beta2.25
Dividend %- Quick Ratio5.30 Sales past 5Y0.80% Gross Margin- 52W Low89.52% ATR0.28
Employees83 Current Ratio5.30 Sales Q/Q- Oper. Margin- RSI (14)39.38 Volatility5.07% 6.32%
OptionableYes Debt/Eq0.17 EPS Q/Q6.30% Profit Margin- Rel Volume0.96 Prev Close4.30
ShortableYes LT Debt/Eq0.17 EarningsSep 09 BMO Payout- Avg Volume285.03K Price4.34
Recom1.90 SMA20-11.70% SMA50-15.20% SMA200-11.22% Volume274,559 Change0.93%
Nov-11-20Initiated Berenberg Buy
Jun-23-20Initiated Cantor Fitzgerald Overweight $14
Jan-28-20Initiated ROTH Capital Buy
Jan-27-20Initiated ROTH Capital Buy
Sep-27-19Upgrade BMO Capital Markets Market Perform → Outperform $5 → $9
Sep-27-19Reiterated H.C. Wainwright Buy $12 → $18
Sep-06-19Initiated Janney Buy $13
Sep-14-17Reiterated Stifel Buy $15 → $12
May-11-17Reiterated Stifel Buy $18 → $15
Mar-15-17Initiated Rodman & Renshaw Buy $16
Nov-09-16Upgrade ROTH Capital Neutral → Buy
Nov-09-16Reiterated Wedbush Outperform $20 → $17
Sep-13-16Reiterated Wedbush Outperform $36 → $20
Sep-13-16Reiterated Stifel Buy $29 → $24
Sep-13-16Downgrade Wells Fargo Outperform → Market Perform
Sep-13-16Downgrade ROTH Capital Buy → Neutral
Sep-13-16Downgrade Cantor Fitzgerald Buy → Hold
Feb-09-16Reiterated Stifel Buy $32 → $29
Dec-04-15Initiated Wells Fargo Outperform
Jul-22-15Initiated Chardan Capital Markets Buy $25
Nov-16-20 05:35PM  
Nov-11-20 07:00AM  
Nov-10-20 04:05PM  
Oct-27-20 06:29AM  
Oct-21-20 07:00AM  
Oct-08-20 07:00AM  
Oct-07-20 07:00AM  
Sep-12-20 09:20AM  
Sep-09-20 07:00AM  
Sep-03-20 04:05PM  
Sep-02-20 04:05PM  
Aug-25-20 07:00AM  
Aug-12-20 07:00AM  
Aug-04-20 07:00AM  
Jul-22-20 07:00AM  
Jul-14-20 06:47AM  
Jul-07-20 09:11PM  
Jun-26-20 12:00PM  
Jun-24-20 08:40AM  
Jun-23-20 04:05PM  
Jun-22-20 07:00AM  
Jun-16-20 04:01PM  
Jun-15-20 07:00AM  
Jun-10-20 11:30AM  
May-26-20 10:50AM  
May-25-20 12:00PM  
May-20-20 07:00AM  
May-15-20 06:24AM  
May-13-20 10:45AM  
May-12-20 08:00AM  
May-06-20 07:00AM  
Apr-28-20 12:34PM  
Apr-22-20 07:20AM  
Mar-24-20 12:00PM  
Mar-16-20 07:00AM  
Feb-19-20 07:00AM  
Feb-16-20 08:50AM  
Feb-06-20 08:06PM  
Feb-05-20 04:36PM  
Jan-28-20 07:30AM  
Jan-23-20 07:00AM  
Jan-22-20 04:01PM  
Jan-21-20 07:00AM  
Jan-10-20 10:08AM  
Jan-09-20 10:02AM  
Jan-08-20 04:01PM  
Dec-19-19 09:17AM  
Dec-17-19 07:36PM  
Dec-04-19 08:19PM  
Dec-03-19 07:59AM  
Dec-02-19 04:35PM  
Nov-12-19 05:55PM  
Nov-06-19 07:00AM  
Nov-05-19 07:00AM  
Oct-31-19 06:38AM  
Oct-21-19 07:00AM  
Oct-01-19 07:30AM  
Sep-30-19 09:29PM  
Sep-26-19 05:35PM  
Sep-25-19 04:05PM  
Sep-19-19 10:30AM  
Sep-18-19 04:05PM  
Sep-16-19 06:23AM  
Sep-02-19 10:30AM  
Aug-28-19 07:00AM  
Aug-14-19 07:30AM  
Aug-07-19 07:00AM  
Jul-24-19 01:54PM  
Jul-23-19 07:00AM  
Jul-19-19 09:41AM  
Jul-17-19 03:33PM  
Jul-11-19 09:05AM  
Jul-10-19 05:53PM  
Jul-08-19 06:02PM  
Jul-05-19 12:04PM  
Jun-28-19 10:10AM  
Jun-25-19 08:00AM  
Jun-24-19 05:53PM  
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which has completed Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. It is also developing an optogenetic product candidate for the patients with advanced retinal disease. In addition, the company has initiated one preclinical program in otology; and three preclinical programs in targeting central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. It has collaboration agreements with Synpromics Limited; University of Florida; Bionic Sight, LLC; and Otonomy, Inc. Applied Genetic Technologies Corporation was founded in 1999 and is headquartered in Alachua, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Krol Patrick Johan Hendrik10% OwnerDec 26Sale5.2481,162425,2891,780,762Dec 30 04:33 PM